Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

BACKGROUND: Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (mRCC). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Zhang, Zhiling, Liu, Ruiqi, Wei, Wensu, Zhang, Zitong, Mai, Lixin, Guo, Shengjie, Han, Hui, Zhou, Fangjian, He, Liru, Dong, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561986/
https://www.ncbi.nlm.nih.gov/pubmed/34727963
http://dx.doi.org/10.1186/s13014-021-01937-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561986/
https://www.ncbi.nlm.nih.gov/pubmed/34727963
http://dx.doi.org/10.1186/s13014-021-01937-9

Ejemplares similares